KDR and cancer: Available agents for the treatment of a number of cancers including mCRC include bevacizumab (monoclonal antibody to the VEGF-A receptor), ramucirumab (anti-VEGF-R2 monoclonal antibody), ziv-aflibercept (VEGF inhibitor), apatinib (anti-VEGF-R2) and regorafenib (VEGFR2-TIE2 inhibition).